FENRIS BIO AS
Signals
- Negativ egenkapital 2025 Bokført egenkapital er negativ (−628k kr).
- Driftsunderskudd 2025 Siste driftsresultat er negativt (−1,4 mill kr).
- Nylig endring 2026-07-27 Aksjekapital registrert 2026-07-27.
FENRIS BIO AS is registered as a limited company in Oslo, Oslo with organisation number 935096049. The business is classified under research and experimental development on natural sciences and engineering (NACE 72.100). The company was incorporated in 2025. Registered share capital is NOK 42,000, divided into 42464 shares. The company's stated purpose is: “Utvikle nye medisiner mot kroniske sykdommer.”. The most recent filed accounts, for the 2025 financial year, show NOK 0 in revenue and NOK −1.4m in operating profit.
Former names: MAGIS MUNDI AS
Key figures · 2025
Financial health · 2025
Solidity capped at Weak because equity is below NOK 100,000.
Who owns FENRIS BIO AS?
FENRIS BIO AS has 10 registered shareholders:
- BLUEFIN AS 25.4%
- C. EMTOR EIENDOM AS 25.4%
- MIKAEL MATHIAS KOLMANNSKOG KERBOEUF 12.9%
- AURIS AS 9.5%
- MITRAL KAPITAL AS 8.6%
- GANDALF AS 8.6%
- PREMCOM BV 4.7%
- REALNOR HOLDING AS 2.1%
- REDROCK HOLDING AS 1.7%
- CHAMONICA AS 0.9%
Frequently asked questions about FENRIS BIO AS
Who owns FENRIS BIO AS?
BLUEFIN AS is the largest registered owner, with 25.4%.
What is the revenue of FENRIS BIO AS?
FENRIS BIO AS had revenue of NOK 0 in 2025.
Who is the general manager of FENRIS BIO AS?
Peter Mollø-Christensen Knudsen is registered as general manager of FENRIS BIO AS.
Where is FENRIS BIO AS based?
FENRIS BIO AS has its business address in Oslo.
Property
25 companies are registered at this address.
The address this company is registered at, from the company register and matched against the cadastre. It does not say who owns the property — a company may be a tenant, and the address is often its accountant's. Source: Brønnøysundregistrene and © Kartverket.
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 02.09.2026.